Treatment of lymphoblastic lymphoma in adults

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 4, 2002, Pages 713-728

  Hoelzer, Dieter ^a   Gökbuget, Nicola ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Chemotherapy; Lymphoblastic lymphoma; Prognostic factors; Stem cell transplantation

Indexed keywords

2 CDA; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ASPARAGINASE; BIOCHEMICAL MARKER; BLEOMYCIN; CD3 ANTIGEN; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSTATIC AGENT; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; METHOTREXATE; NELARABINE; PREDNISONE; T LYMPHOCYTE ANTIBODY; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MODEL; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL FEATURE; CLINICAL PROTOCOL; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LYMPHOBLASTOMA; MEDIASTINUM TUMOR; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; REVIEW; T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT OUTCOME; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DOSE REGIMEN; SALVAGE THERAPY; SKULL IRRADIATION; WHOLE BODY RADIATION;

EID: 0036950062     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0230     Document Type: Review

References (62)

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909-3918.
2. Groves FD, Linet MS, Travis LB & Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. Journal of the National Cancer Institute 2000; 92: 1240-1251.
3. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69-86.
4. Hoelzer D, Gokbuget N, Digel W et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002; 99: 4379-4385.
5. Foon KA, Herzog P, Billing RJ et al. Immunologic classification of childhood acute lymphocytic leukemia. Cancer 1981; 47: 280-284.
6. Jaffe ES & Berard CW. Lymphoblastic lymphoma, a term rekindled with new precision. Annals of Internal Medicine 1978; 89: 415-417.
7. Bernasconi C, Brusamolino E, Lazzarino M et al. Lymphoblastic lymphoma in adult patients: Clinicopathological features and response to intensive multiagent chemotherapy analogous to that used in acute lymphoblastic leukemia. Annals of Oncology 1990; 1: 141-146.
8. Santini G, Congiu AM, Coser P et al. Autologous bone marrow transplantation for adult advanced stage lymphoblastic lymphoma in first CR. A study of the NHLCSG. Leukemia 1991; 5 (supplement 1): 42-45.
9. Morel P, Lepage E, Brice P et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. Journal of Clinical Oncology 1992; 10: 1078-1085.
10. Zinzani PL, Bendandi M, Visani G et al. Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leukemia & Lymphoma 1996; 23: 577-582.
11. Bouabdallah R, Xerri L, Bardou VJ et al. Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Annals of Oncology 1998; 9: 619-625.
12. Sweetenham JW, Santini G, Qian W et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. Journal of Clinical Oncology 2001; 19: 2927-2936.
13. Reiter A, Schrappe M, Ludwig WD et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95: 416-421.
14. Hoelzer D, Arnold R, Freund M et al. Characteristics, outcome and risk factors in adult T-lineage acute lymphoblastic leukemia (ALL). Blood 1999; 94: 2926a.
15. Engelhard M, Brittinger G, Gerhartz HH et al. Lymphoblastic lymphoma: results of a prospective treatment trial (BMFT study). British Journal of Haematology 1996; 93: 1391a.
16. Soslow RA, Baergen RN & Warnke RA. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer 1999; 85: 2648-2654.
17. Maitra A, McKenna RW, Weinberg AG et al. Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. American Journal of Clinical Pathology 2001; 115: 868-875.
18. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Seminars in Oncology 1980; 7: 332-339.
19. Voakes JB, Jones SE & McKelvey EM. The chemotherapy of lymphoblastic lymphoma. Blood 1981; 57: 186-188.
20. Liang R, Todd D, Chan TK et al. Intensive chemotherapy for adult lymphoblastic lymphomas. Cancer Chemotherapy & Pharmacology 1991; 29: 80-82.
21. Kaiser U, Uebelacker I & Havemann K. Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients. Leukemia & Lymphoma 1999; 36: 101-108.
22. Coleman CN, Cohen JR, Burke JS & Rosenberg SA. Lymphoblastic lymphoma in adults: results of a pilot protocol. Blood 1981; 57: 679-684.
23. Coleman CN, Picozzi VJ Jr, Cox RS et al. Treatment of lymphoblastic lymphoma in adults. Journal of Clinical Oncology 1986; 4: 1628-1637.
24. Colgan JP, Andersen J, Habermann TM et al. Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma. Leukemia & Lymphoma 1994; 15: 291-296.
25. Chen YC, Ho CL, Kao WY et al. Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients. Annals of Hematology 2001; 80: 647-652.
26. Levine AM, Forman SJ, Meyer PR et al. Successful therapy of convoluted T-lymphoblastic lymphoma in the adult. Blood 1983; 61: 92-98.
27. Santini G, Congiu A, D'Amico T et al. Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukaemia (ALL) in adults: relationships and therapeutic perspectives. Bone Marrow Transplantation 1989; 4 (supplement 1): 106-107.
28. Slater DE, Mertelsmann R, Koziner B et al. Lymphoblastic lymphoma in adults. Journal of Clinical Oncology 1986; 4: 57-67.
29. Daenen S, van Imhoff GW, Haaxma-Reiche H et al. Acute lymphoblastic leukemia: single center experience with modified chemotherapy. Blood 1995; 86(S1): 754a.
30. Thomas D, Kantarjian H, O'Brien S et al. Outcome with the hyper-CVAD regimen in lymphoblastic lymphoma. Proc ASCO 1999; 18: 38a.
31. Yeh KH, Cheng AL, Su IJ et al. Prognostic significance of immunophenotypes in adult lymphoblastic lymphomas. Anticancer Research 1997; 17: 2269-2272.
32. Anderson JR, Wilson JF, Jenkin RDT et al. Childhood non-Hodgkin's lymphoma: the results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). British Journal of Haematology 1983; 308: 559-565.
33. Salloum E, Henry-Amar M, Caillou B et al. Lymphoblastic lymphoma in adults: a clinicopathological study of 34 cases treated at the Institut Gustave-Roussy. European Journal of Cancer and Clinical Oncology 1988; 24: 1609-1616.
34. Shepherd SF, A'Hern RP & Pinkerton CR. Childhood T-cell lymphoblastic lymphoma-does early resolution of mediastinal mass predict for final outcome? The United Kingdom Children's Cancer Study Group (UKCCSG) British Journal of Cancer 1995; 72: 752-756.
35. Reiter A, Schrappe M, Tiemann M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999; 94: 3294-3306.
36. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is[18F] FDG-PET a valid alternative to conventional diagnostic methods? Journal of Clinical Oncology 2001; 19: 414-419.
37. Zinzani PL, Martelli M, Magagnoli M et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients, Blood 1999; 94: 3289-3293.
38. Mott MG, Eden OB & Palmer MK. Adjuvant low dose radiation in childhood non-Hodgkin's lymphoma (report from the United Kingdom Childrens' Cancer Study Group-UKCCSG). British Journal of Cancer 1984; 50: 463-469.
39. Tubergen DG, Krailo MD, Meadows AT et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. Journal of Clinical Oncology 1995; 13: 1368-1376.
40. Hvizdala EV, Berard C, Callihan T et al. Lymphoblastic lymphoma in children-a randomized trial comparing LSA2-L2 with the A-COP+therapeutic regimen: a Pediatric Oncology Group Study. Journal of Clinical Oncology 1988; 6: 26-33.
41. Camitta BM, Lauer SJ, Casper JT et al. Effectiveness of asix-drug regimen (APO) without local irradiation for treatment of mediastinal lymphoblastic lymphoma in children. Cancer 1985; 56: 738-741.
42. Weinstein HJ, Cassady JR & Levey R. Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. Journal of Clinical Oncology 1983; 1: 537-541.
43. Levine AM, Taylor CR, Schneider DR et al. Immunoblastic sarcoma of T-cell versus B-cell origin: I. Clinical features. Blood 1981; 58: 52-61.
44. Jost LM, Jacky E, Dommann-Scherrer C et al. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients. Annals of Oncology 1995; 6: 445-451.
45. Mazza P, Bertini M, Macchi S et al. Lymphoblastic lymphoma in adolescents and adults. Clinical, pathological and prognostic evaluation. European Journal of Cancer and Clinical Oncology 1986; 22: 1503-1510.
46. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 329: 987.
47. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998; 92: 4491-4508.
48. Ferrando AA, Neuberg DS, Staunton J et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75-87.
49. Milpied N, Ifrah N, Kuentz M et al. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. British Journal of Haemotology 1989; 73: 82-87.
50. Verdonck LF, Dekker AW, de Gast GC et al. Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission. Journal of Clinical Oncology 1992; 10: 644-646.
51. Baro J, Richard C, Sierra J et al. Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy. Bone Marrow Transplantation 1992; 10: 33-38.
52. Conde E, Zuazu J, Lopez-Guillermo A et al. Autologous stem cell transplantation (ASCT) for lymphoblastic lymphoma (LBL). Blood 1999; 94: 2130a.
53. Sweetenham JW, Liberti G, Pearce R et al. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. Journal of Clinical Oncology 1994; 12: 1358-1365.
54. Peniket AJ, Ruiz de Elvira MC, Taghipour G et al. Allogeneic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival is worse because of higher treatment related mortality - a report of 764 cases from the EBMT lymphoma registry. Blood 1997; 90: 1121a.
55. van Besien KW, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. American Journal of Medicine 1996; 100: 299-307.
56. van Besien K, Przepiorka D, Mehra R et al. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. Journal of Clinical Oncology 1996; 14: 3036-3042.
57. Lauer SJ, Pinkel D, Buchanan GR et al. Cytosine arabinoside/cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia. Cancer 1987; 60: 2366-2371.
58. Hoelzer D, Thiel E, Löffler H et al. Intensified chemotherapy and mediastinal irradiation in adult T-cell acute lymphoblastic leukemia. In Anonymous (ed.) Acute Lymphoblastic Leukemia, pp 221-229. City Alan R. Liss, 1990.
59. Amylon MD, Shuster J, Pullen J et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 1999; 13: 335-342.
60. Schrappe M, Reiter A, Ludwig WD et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95: 3310-3322.
61. Pui CH, Sallan S, Relling MV et al. International Childhood Acute Lymphoblastic Leukemia Workshop: Sausalito, CA, 30 November-1 December 2000. Leukemia 2001; 15: 707-715.
62. Bassan R, Pogliani E, Lerede T et al. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study. Haematologica 1999; 84: 1088-1093.